Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Becker

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Journal of Clinical Microbiology|November 24, 2012
A laboratory-developed TaqMan Array Card for simultaneous detection of 19 enteropathogensJie Liu, Jean Gratz, Caroline Amour, et al.
Antimicrobial Agents and Chemotherapy|February 21, 2008
Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteersYing Jun Cao, Charles W Flexner, Shelia Dunaway, et al.
Journal of the International AIDS Society|July 14, 2010
Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunitiesSusan C Kim, Stephen Becker, Carl Dieffenbach, et al.
The Journal of Infectious Diseases|April 2, 2016
Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan AfricaAndrew N Phillips, Valentina Cambiano, Paul Revill, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2019
Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority TrialWillem Daniel Francois Venter, Andrew Kambugu, Matthew F Chersich, et al.
Antimicrobial Agents and Chemotherapy|April 25, 2007
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjectsNimalie D Stone, Shelia B Dunaway, Charles Flexner, et al.
Antiviral Therapy|October 2, 2003
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adultsJacob P Lalezari, Edwin DeJesus, Donald W Northfelt, et al.
Nature Medicine|February 17, 2009
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cellsRonald T Mitsuyasu, Thomas C Merigan, Andrew Carr, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Journal of Clinical Microbiology|November 24, 2012
A laboratory-developed TaqMan Array Card for simultaneous detection of 19 enteropathogensJie Liu, Jean Gratz, Caroline Amour, et al.
Antimicrobial Agents and Chemotherapy|February 21, 2008
Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteersYing Jun Cao, Charles W Flexner, Shelia Dunaway, et al.
Journal of the International AIDS Society|July 14, 2010
Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunitiesSusan C Kim, Stephen Becker, Carl Dieffenbach, et al.
The Journal of Infectious Diseases|April 2, 2016
Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan AfricaAndrew N Phillips, Valentina Cambiano, Paul Revill, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2019
Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority TrialWillem Daniel Francois Venter, Andrew Kambugu, Matthew F Chersich, et al.
Antimicrobial Agents and Chemotherapy|April 25, 2007
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjectsNimalie D Stone, Shelia B Dunaway, Charles Flexner, et al.
Antiviral Therapy|October 2, 2003
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adultsJacob P Lalezari, Edwin DeJesus, Donald W Northfelt, et al.
Nature Medicine|February 17, 2009
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cellsRonald T Mitsuyasu, Thomas C Merigan, Andrew Carr, et al.
Pageof 5